This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical

REIMAGINING THE TREATMENT OF HEARING

LOSS Corporate Overview July 2021 Exhibit 99.1

This presentation contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,

including without limitation statements regarding the interpretation and implications of the results of the Phase 2a study as well as the FX-322-112 and the FX-322-111 studies, the timing and results of top-line data from the Phase 1b study in

severe SNHL, the design and timing of future studies of and clinical development path for FX-322, the results and implications of the Phase 1/2 durability of response data, the timing of phase 2 meetings with the FDA and future pivotal studies, the

ability of our technology platform to provide patient benefit, the impact of COVID-19 on the Company's on-going and planned clinical trials and business, future milestone and royalty payments under the license and collaboration agreement with

Astellas Pharma Inc. ("Astellas"), the sufficiency of the Company's cash, cash equivalents and short-term investments, estimates of the size of the hearing loss population and population at risk for hearing loss, estimates of the

commercial opportunity of FX-322 and the impact on existing treatment paradigms, the timing of the remyelination program, and the potential application of the PCA platform to other diseases. These forward-looking statements are based on

management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially

different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Company's ongoing and planned clinical trials,

research and development and manufacturing activities, the relocation of the Company's offices and laboratory facilities, the Company's business and financial markets; Frequency Therapeutics (the "Company") has incurred and

will continue to incur significant losses and is not and may never be profitable; need for additional funding to complete development and commercialization of any product candidate; the Company's dependence on the development of FX-322; the

unproven approach of the PCA platform; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; limited experience successfully obtaining marketing approval for and commercializing product candidates; the

results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other

regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval;

costly and damaging litigation, including related to product liability, intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct

by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with laws and regulations, including healthcare and environmental, health, and safety laws and

regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property; security breaches or failure to protect private personal information; attracting and retaining key personnel; and ability to manage growth.

These and other important factors discussed under the caption "Risk factors" in the Company's Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2021 and its other reports filed with the SEC could cause

actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While the Company

may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing

the Company's views as of any date subsequent to the date of this presentation. Forward-Looking Statements and Other Disclaimers c Frequency Therapeutics, Inc.

Frequency Today: Guided by a Clear

Signal Leading the field of hearing restoration First ever known clinical studies demonstrating hearing improvements

Defining the Target, Expanding the

Pipeline Learnings from exploratory studies support new Phase 2 trials and help define path forward Working to expand our pipeline for hearing therapeutics and for other degenerative diseases

c Frequency Therapeutics, Inc.

Today's Hearing Loss Market Has No Restorative Treatments $980 Billion Only 20% market penetration for Hearing Aids Lost annually due to untreated hearing loss globally* ~41 Million SNHL patients in U.S. ~$10 Billion US hearing aid market

annual sales *Source: World Health Organization

July, 2020 "Hearing loss is the

largest potentially modifiable risk factor for developing dementia" Hearing Loss May Have a Significant Impact on Overall Health DEMENTIA DEPRESSION Increased risks with untreated hearing loss 50% 41% JAMA Nov 8, 2018 Deal J, et al. Incident

Hearing Loss and Comorbidity. A Longitudinal Administrative Claims Study.

c Frequency Therapeutics, Inc. Since

2014 Frequency has been driving a powerful new approach to tissue and cellular regeneration aimed at developing new therapeutics for conditions where there are no treatment options. Frequency Therapeutics: A Vision Built on Regeneration

"Analysis of hair cells, auditory

nerve fibers and strial tissues shows that the degree of hearing loss is well predicted from the amount of hair cell loss." - Journal of Neuroscience July 2020 Sensory Hair Cells Progenitor Cells Missing Sensory Hair Cells The Problem:

Missing Sensory Hair Cells in the Cochlea

Solution: A Therapy to Address the

Underlying Pathology Synergy between pathways aims to activate progenitor cells and regenerate sensory cells in the cochlea

Intelligibility of Speech and Sound

- A Major Unmet Clinical Need For those with sensorineural hearing loss, words may be indistinguishable - impacting their ability to understand and communicate

c Frequency Therapeutics, Inc. of

words in English rely on the use of fricative consonants of words in Mandarin of words in Spanish 40% 42% 55%

c Frequency Therapeutics, Inc.

Increasing Focus on Hearing Clarity Intelligibility (Clarity) measured with word recognition and words-in-noise tests Word Recognition Test List of 50 monosyllabic words Single words played in quiet Words-in-Noise Test Background noise from multiple

voices Played at different signal-to-noise ratios Audibility (Loudness) measured with pure tone test (Standard, Validated Tests)

c Frequency Therapeutics, Inc.

Directly Targeting the Regeneration of Sensory Hair Cells in the Cochlea FX-322 is administered via a standard intratympanic injection, a common procedure ENTs perform routinely The injection concentrates FX-322 in the cochlear region critical for

speech intelligibility

FX-322 Clinical Profile Informed by

Broad Range of Learning Studies [Detail from subjects across all single-dose studies will provide key insights into potential responders] Enrolled Phase 1/2 (FX-322-201) Phase 1b (FX-322-111) Phase 1b (FX-322-112) Phase 2a (FX-322-202) Subjects with

mild-to-moderately severe SNHL Subjects with mild-to-severe SNHL Subjects with presbycusis (age-related hearing loss) mild-to-mod. severe Subjects with mild-to-moderately severe SNHL Subjects with Noise-Induced or Sudden SNHL Subjects with

Noise-Induced or Sudden SNHL NO SUBJECTS with Noise-Induced or Sudden SNHL Subjects with Noise-Induced or Sudden SNHL Age 18-65; N=23 Age 18-65; N=33 Age 66-85; N=30 Age 18-65; N=95 Single administration Single administration Single administration

Four administration regimen Double-blind, placebo controlled, multi-center, randomized study Open-label, multi-center, randomized study FX-322 injected in one ear - contra lateral ear acted as control Placebo controlled Multi-center,

randomized Double-blind, placebo controlled, multi-center, randomized study Clinically meaningful and statistically significant improvements in word recognition scores in patients with measurable word recognition deficits Clinically meaningful and

statistically significant improvements in word recognition scores In patients with measurable word recognition deficits No significant treatment effect observed with FX-322 compared to placebo No response in placebo groups or in untreated ears

Unexpected increase in word rec (WR) scores in placebo group suggests bias due to trial design. Lack of reliable baseline scores, left company unable to evaluate hearing improvements across cohorts Favorable safety and tolerability profile Favorable

safety and tolerability profile Favorable safety and tolerability profile Favorable safety and tolerability profile c Frequency Therapeutics, Inc. Phase 1b (FX-322-113) Severe sensorineural hearing loss Subjects with severe SNHL Age 18-65; N=31

Single Administration Single administration Placebo controlled Multi-center, randomized Study enrolling Data anticipated in second half of 2021

End of Phase 2a Study Conclusions*

There was an unexpected increase in WR scores in the placebo group, which did not occur in previous FX-322 trials and exceeded well-established published standards. Potentially suggesting bias due to trial design As a result of unreliable baseline

WR scores in the placebo group due to potential trial design bias, the Company was unable to evaluate hearing improvements in WR scores for FX-322 dosing regimens versus placebo. Four weekly injections of FX-322 did not demonstrate improvements in

any other hearing measures versus placebo Frequency Therapeutics, Inc. FX-322 continues to have a favorable safety and tolerability profile. Although there was a higher rate of AEs noted in this 4x dosing trial, there were no treatment-associated

serious adverse events observed and no patients withdrew from the study due to treatment-associated AEs. *Additional study detail and data tables provided in SEC Form 8k dated June 30, 2021

Two Independent Studies (FX-322-201,

FX-322-111) Show Hearing Improvements with Single Dose Phase 1b Study FX-322-111 Overview Compared different FX-322 administration conditions Open-label, multi-center, randomized study Mild to severe subjects, age 18-65 (n=33) Study Results 34% of

subjects achieved 10% or greater absolute improvement in word recognition (WR) in treated ear Statistically significant and clinically meaningful improvements in WR Favorable safety profile Phase 1/2 Study FX-322-201 Overview Placebo-controlled,

multi-center, randomized study Mild to moderately severe subjects, age 18-65 (n=23) NIHL/SSNHL Study Results 33% of subjects achieved 10% or greater absolute improvement in word recognition in treated ear Statistically significant and clinically

meaningful improvements in WR No meaningful changes in placebo group Favorable safety profile *Total of 33 patients enrolled in study, 32 subjects completed 90-day clinical assessment period

c Frequency Therapeutics, Inc.

FX-322 Phase 1/2 Durability Data: Patients Show Sustained Hearing Improvements 13-21 Months After Initial Dosing 50W 50W 25W 50W 50W 50W 50W 50W 50W 50W 50W 50W 50W 50W 25W Month 16 Month 21** Month 19** Month 13** Month 21** 14 34 30 7 16 12 20

39 35 26 47 38 29 38 22 Baseline - Correct words out of 50 Day 90 - Correct words out of 50 1-2 Years - Correct words out of 50 *25W = 25 Word test performed outside an official study site at 13-18 months after dosing; results scaled to 50 words 50W

= 50 Word test performed under a formal protocol at original study site at 18-21 months after dosing **Since FX-322 dosing Three patients who had durable improvements in intelligibility also had pure tone audiometry improvements of 10 - 15 dB

at the highest frequency tested (8k Hz) Key Findings Preliminary evidence indicating a durable benefit of hearing clarity

DOI: 10.1097/MAO.0000000000003120 c

Frequency Therapeutics, Inc. FX-322 Clinical Data Published in Leading Journal FX-322 Phase 1/2 and drug delivery studies Improved Speech Intelligibility in Subjects with Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in

a Phase 1b Study (W.J. McLean, et. al. 2021) Pre-eminent, peer-reviewed journal in the field

Next Steps for Continued FX-322

Clinical Development Important learnings informing continued FX-322 development Understanding specific populations where FX-322 demonstrates benefit Lead-in baseline assessments and other controls may mitigate study design bias Build off totality of

study subject data Anticipate activating additional FX-322 Phase 2 placebo-controlled studies in H2 2021 Continuum of data will further inform understanding of the patients and conditions where FX-322 may have the greatest impact Clinical data

demonstrate potential of FX-322 as a restorative treatment for SNHL Two FX-322 single administration studies have demonstrated treatment benefit Favorable safety profile

Repair of neurological damage is the

major unmet need in MS Currently approved immunomodulators do not restore myelin Remyelination of damaged neurons has potential reverse neurological damage Target population for remyelination represents 50% of MS patients Using PCA approach to

address restoration in MS patients Pre-clinical data has demonstrated potential to remyelinate with proprietary small molecule combinations Research efforts underway to confirm optimal combination of molecules for clinical program Strong IP

portfolio Remyelination Program for Multiple Sclerosis c Frequency Therapeutics, Inc.

Harnessing Innate Biology

Progenitors already located within target tissue Frequency: Developing a Platform Approach that Reduces the Complexity of Regenerative Medicine c Frequency Therapeutics, Inc. No Change to Genome Activating native programs, reducing safety concerns

Ease of Manufacturing Use of small molecules: no need to remove or grow cells ex vivo

c Frequency Therapeutics, Inc.

Summary and Financial Profile Ex-US Partnership with Strong Potential Milestones and Royalties $194.9 Million in Cash and Cash Equivalents* Runway into 2023 *As of March. 31, 2021. Excludes restricted cash Defining FX-322 Development Path and

Advancing New Studies Continued clinical validation and development progress Two Single Dose FX-322 Studies Show Hearing Improvements Statistical significance in key measure of hearing clarity

REIMAGINING THE TREATMENT OF HEARING

LOSS Corporate Overview July 2021

c Frequency Therapeutics, Inc.

c Frequency Therapeutics, Inc. Broad

Potential of Progenitor Cell Activation Approach

c Frequency Therapeutics, Inc.

Origin of Frequency Therapeutics Tissue-Specific, Pre-programmed Stem Cells Decoding Intestinal Regeneration Langer and Karp publish small molecules activate intestinal progenitors Enabling Cochlear Regeneration Same cues reactivate normally

inactive progenitors in the cochlea Frequency Therapeutics Small molecule therapeutics show clinical proof of concept Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny Clonal Expansion of Lgr5-Positive Cells